Business

Mass. Movers

Traders cheer Biogen Idec’s MS drug sales

Last week, Standard & Poor’s raised its rating to “A-” from “BBB+” on Weston-based Biogen Idec.

Globe File Photo/2013

Last week, Standard & Poor’s raised its rating to “A-” from “BBB+” on Weston-based Biogen Idec.

Advertisement

MarketWatch.com said sales of Biogen Idec Inc.’s newest multiple sclerosis treatment were “causing murmurs on Wall Street and lifting shares of the company” as traders noted a strong first two weeks of sales for Tecfidera. Analyst Michael Yee of RBC Capital Markets said second-week sales were 42 times first-week sales, far outpacing those for competing treatments. He cited “very high awareness with both physicians and patients” and a “strong combination of efficacy and safety.”

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com